246 related articles for article (PubMed ID: 25306859)
1. Prostate-specific antigen screening, why have the guidelines changed?
Sountoulides P; Moutzouris G
Expert Rev Anticancer Ther; 2014 Nov; 14(11):1277-81. PubMed ID: 25306859
[TBL] [Abstract][Full Text] [Related]
2. Use of low free to total PSA ratio in prostate cancer screening: detection rates, clinical and pathological findings in Brazilian men with serum PSA levels <4.0 ng/mL.
Faria EF; Carvalhal GF; dos Reis RB; Tobias-Machado M; Vieira RA; Reis LO; Nogueira L; Machado RD; Freitas CH; Magnabosco WJ; Mauad EC; Carvalho AL
BJU Int; 2012 Dec; 110(11 Pt B):E653-7. PubMed ID: 22892057
[TBL] [Abstract][Full Text] [Related]
3. Prostate Cancer Screening and the Associated Controversy.
Tabayoyong W; Abouassaly R
Surg Clin North Am; 2015 Oct; 95(5):1023-39. PubMed ID: 26315521
[TBL] [Abstract][Full Text] [Related]
4. Prostate-specific antigen screening for prostate cancer in older men in the United States of America.
Black A; Berg CD
Gerontology; 2012; 58(4):331-6. PubMed ID: 22343605
[TBL] [Abstract][Full Text] [Related]
5. Histological inflammation and risk of subsequent prostate cancer among men with initially elevated serum prostate-specific antigen (PSA) concentration in the Finnish prostate cancer screening trial.
Yli-Hemminki TH; Laurila M; Auvinen A; Määttänen L; Huhtala H; Tammela TL; Kujala PM
BJU Int; 2013 Oct; 112(6):735-41. PubMed ID: 23746332
[TBL] [Abstract][Full Text] [Related]
6. Early detection, PSA screening, and management of overdiagnosis.
Borza T; Konijeti R; Kibel AS
Hematol Oncol Clin North Am; 2013 Dec; 27(6):1091-110, vii. PubMed ID: 24188254
[TBL] [Abstract][Full Text] [Related]
7. Updated Japanese Urological Association Guidelines on prostate-specific antigen-based screening for prostate cancer in 2010.
;
Int J Urol; 2010 Oct; 17(10):830-8. PubMed ID: 20825509
[TBL] [Abstract][Full Text] [Related]
8. Screening for prostate cancer: the current evidence and guidelines controversy.
Gomella LG; Liu XS; Trabulsi EJ; Kelly WK; Myers R; Showalter T; Dicker A; Wender R
Can J Urol; 2011 Oct; 18(5):5875-83. PubMed ID: 22018148
[TBL] [Abstract][Full Text] [Related]
9. PSA in screening for prostate cancer: more good than harm or more harm than good?
Duffy MJ
Adv Clin Chem; 2014; 66():1-23. PubMed ID: 25344984
[TBL] [Abstract][Full Text] [Related]
10. [Focus on the screening for prostate cancer by PSA].
Roumeguère T; Van Velthoven R
Rev Med Brux; 2013 Sep; 34(4):311-9. PubMed ID: 24195246
[TBL] [Abstract][Full Text] [Related]
11. Critical appraisal of prostate-specific antigen in prostate cancer screening: 20 years later.
Pienta KJ
Urology; 2009 May; 73(5 Suppl):S11-20. PubMed ID: 19375622
[TBL] [Abstract][Full Text] [Related]
12. [Early detection of cancer of the prostate. Pros and cons].
Hoesl CE; Altwein JE
MMW Fortschr Med; 2005 Apr; 147(14):32, 34-6. PubMed ID: 15887681
[TBL] [Abstract][Full Text] [Related]
13. Screening for prostate cancer.
Croswell J; Shin YR
Am Fam Physician; 2013 Feb; 87(4):283-4. PubMed ID: 23418805
[No Abstract] [Full Text] [Related]
14. Towards an optimal interval for prostate cancer screening.
van Leeuwen PJ; Roobol MJ; Kranse R; Zappa M; Carlsson S; Bul M; Zhu X; Bangma CH; Schröder FH; Hugosson J
Eur Urol; 2012 Jan; 61(1):171-6. PubMed ID: 21840117
[TBL] [Abstract][Full Text] [Related]
15. Clinical performance of serum prostate-specific antigen isoform [-2]proPSA (p2PSA) and its derivatives, %p2PSA and the prostate health index (PHI), in men with a family history of prostate cancer: results from a multicentre European study, the PROMEtheuS project.
Lazzeri M; Haese A; Abrate A; de la Taille A; Redorta JP; McNicholas T; Lughezzani G; Lista G; Larcher A; Bini V; Cestari A; Buffi N; Graefen M; Bosset O; Le Corvoisier P; Breda A; de la Torre P; Fowler L; Roux J; Guazzoni G
BJU Int; 2013 Aug; 112(3):313-21. PubMed ID: 23826841
[TBL] [Abstract][Full Text] [Related]
16. [Screening for prostate cancer: present status and future perspectives].
Ito K
Nihon Rinsho; 2014 Dec; 72(12):2198-203. PubMed ID: 25518358
[TBL] [Abstract][Full Text] [Related]
17. Informed decision making on PSA testing for the detection of prostate cancer: an evaluation of a leaflet with risk indicator.
van Vugt HA; Roobol MJ; Venderbos LD; Joosten-van Zwanenburg E; Essink-Bot ML; Steyerberg EW; Bangma CH; Korfage IJ
Eur J Cancer; 2010 Feb; 46(3):669-77. PubMed ID: 20022239
[TBL] [Abstract][Full Text] [Related]
18. A Calculator for Prostate Cancer Risk 4 Years After an Initially Negative Screen: Findings from ERSPC Rotterdam.
Roobol MJ; Zhu X; Schröder FH; van Leenders GJ; van Schaik RH; Bangma CH; Steyerberg EW
Eur Urol; 2013 Apr; 63(4):627-33. PubMed ID: 22841675
[TBL] [Abstract][Full Text] [Related]
19. Disease-specific survival of men with prostate cancer detected during the screening interval: results of the European randomized study of screening for prostate cancer-Rotterdam after 11 years of follow-up.
Zhu X; van Leeuwen PJ; Bul M; Otto SJ; de Koning HJ; Bangma CH; Schröder FH; Roobol MJ
Eur Urol; 2011 Aug; 60(2):330-6. PubMed ID: 21601352
[TBL] [Abstract][Full Text] [Related]
20. Mass screening of 12,027 elderly men for prostate carcinoma by measuring serum prostate specific antigen.
Zhang HF; Wang HL; Xu N; Li SW; Ji GY; Li XM; Pan YZ; Zhang L; Zhao XJ; Gao HW
Chin Med J (Engl); 2004 Jan; 117(1):67-70. PubMed ID: 14733776
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]